BIOLINERX Ltd/S (NASDAQ:BLRX) issued its earnings results on Thursday. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.06), reports.

Shares of BIOLINERX Ltd/S stock traded down $0.01 during midday trading on Friday, hitting $0.70. The company’s stock had a trading volume of 391,694 shares, compared to its average volume of 1,728,884. The stock has a market cap of $78.77 million, a PE ratio of -2.59 and a beta of 0.87. BIOLINERX Ltd/S has a 1-year low of $0.67 and a 1-year high of $1.84.

A hedge fund recently bought a new stake in BIOLINERX Ltd/S stock. Fosun International Ltd bought a new position in BIOLINERX Ltd/S (NASDAQ:BLRX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,357,415 shares of the biotechnology company’s stock, valued at approximately $1,412,000. Fosun International Ltd owned 1.27% of BIOLINERX Ltd/S as of its most recent SEC filing. Institutional investors own 34.69% of the company’s stock.

A number of equities analysts recently issued reports on the company. Maxim Group restated a “buy” rating and issued a $2.00 target price on shares of BIOLINERX Ltd/S in a report on Thursday. Oppenheimer set a $3.00 target price on BIOLINERX Ltd/S and gave the stock a “buy” rating in a report on Friday. Zacks Investment Research upgraded BIOLINERX Ltd/S from a “sell” rating to a “hold” rating in a report on Wednesday. HC Wainwright set a $4.00 target price on BIOLINERX Ltd/S and gave the stock a “buy” rating in a report on Friday. Finally, ValuEngine upgraded BIOLINERX Ltd/S from a “hold” rating to a “buy” rating in a report on Tuesday, October 16th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $2.50.

TRADEMARK VIOLATION NOTICE: “BIOLINERX Ltd/S (BLRX) Releases Earnings Results, Meets Estimates” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at


BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

Featured Article: How are the companies in the S&P 500 selected?

Earnings History for BIOLINERX Ltd/S (NASDAQ:BLRX)

Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with's FREE daily email newsletter.